Boomerang Ventures

SynchNeuro Secures Seed Funding From Boomerang Ventures
In the News
Source: CityBiz SynchNeuro, a Philadelphia-based health-technology startup founded by neurosurgeon Dr. Casey Halpern, has secured seed funding from Boomerang Ventures. The company is developing a non-invasive EEG-based platform that decodes brain-signal activity into metabolic insights, aiming to support individuals with prediabetes and early-stage Type 2 diabetes. The investment will help expand operations and accelerate product development.

SynchNeuro is a Boomerang Ventures Portfolio Company

Source: CityBiz

SynchNeuro a Philadelphia-based health-technology startup, has received a seed investment from Boomerang Ventures, the companies said. Financial terms weren’t disclosed.

Boomerang Ventures, headquartered in Indianapolis, operates as both a venture studio and a fund, focusing on early-growth companies in connected health technology. The firm backs startups across a range of healthcare-tech domains, including value-based care, remote monitoring, med-tech devices, and digital health platforms.

Its portfolio includes companies such as:

  • Aware Healthwhich provides musculoskeletal-care solutions aimed at reducing costs and unnecessary imaging.
  • Pelvital USA, Inc. (branded “Flyte®”), a women’s-health med-tech company offering new treatment options for pelvic-floor disorders.
  • Lizzy Care, which uses AI-driven analytics and real-time care coordination for dementia and memory-care at home.
  • GEOH, a company focused on software and services for home-health-care agencies.

SynchNeuro plans to use the new investment to expand operations and accelerate the development of its real-time monitoring platform.

Founded by neurosurgeon Dr. Casey Halpern, SynchNeuro is developing a non-invasive system that decodes brain-signal activity (EEG) into cardiometabolic data. The technology interprets EEG readings to estimate glucose levels and other metabolic indicators, offering a potential alternative to traditional glucose monitors. The company says its platform is designed to give individuals with prediabetes or early-stage Type 2 diabetes more proactive insight into their metabolic health.

Source: CityBiz, November 25, 2025

Boomerang Ventures
Loading...